This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Evaluating Evommune's EVO756 for Treating Chronic Inducible Urticaria
Ticker(s): EVMN, NVS, SNY, RHHBY, REGNWho's the expert?
Institution: University of Toledo
- Director of the Toledo Institute of Clinical Research & Clinical Assistant Professor at the University of Toledo Medical Center.
- Currently manages 4-5 patients with cold urticaria.
- President Toledo Institute of Clinical Research; Actively involved in clinical research and has been author of various chapters and papers.
Interview GoalThis conversation will focus on the landscape of Chronic Inducible Urticaria along with the potential of Evommune, Incs' EVO756
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
